Bangalore, 8 May 2017: Parry Nutraceuticals (a division of EID Parry and part of the Murugappa Group) has received the U.S. Food and Drug Administration (US-FDA) approval for its India facility for organic microalgae cultivation and processing. The fully organic, 130 acres – 600 TPA facility, located in Oonaiyur, Pudukottai district, Tamil Nadu, has received the Establishment Inspection Report (EIR) from the US-FDA following an inspection of the facility in July 2016.
Muthu Murugappan, Business Head, Parry Nutraceuticals, speaking about the US-FDA approval, said, “We are proud of this result, as it is a testament to our on-going commitment to maintaining superior quality systems. We are a preferred supplier of micro-algal health supplements for several leading nutraceutical brands in over 35 countries. This approval will further enhance our reputation as a leader in micro-algal technology.”
Parry Nutraceuticals is also stepping up its new product development (NPD) efforts to meet increasing customer demand for value-added products based on microalgae. Elaborating on the plans, Muthu Murugappan added, “Our new product strategy is to provide value addition to our existing micro-algal range. Some of the products that we will bring to the market over the next two years include Organic Chlorella, Spirulina Granules, CO2 Extracted Lutein and Algal Beta Glucan, to name a few. Other exciting new areas currently under development include vegan algal proteins, chlorophyll and algae (vegan) omega-3s.”
Parry Nutraceuticals has more than 2 decades of experience in cultivation and processing of microalgae-based nutraceuticals including Organic Spirulina, a recognised dietary supplement with high protein content, Astaxanthin, a powerful antioxidant, Organic Chlorella, which helps in detoxification & healthy ageing, and other Phytochemicals. Parry Nutraceuticals is known for its superior product quality and safety and boasts of an enviable global customer base for its Nutritional Supplements in over 35 countries. Parry Nutra’s US arm, Valensa International based in Florida, is a wholly owned subsidiary of EID Parry which specialises in development of condition-specific nutraceuticals (addressing joint, eye and cardio-vascular health issues), backed by clinical science and IP. In 2014, EID Parry acquired Alimtec SA, based in Chile, for cultivation of Heamatococcus Pluvialis for extraction of Astaxanthin, a powerful antioxidant, marketed by Valensa under its trademark Zanthin® Natural Astaxanthin. (http://www.parrynutraceuticals.com)
